Baylink is leveraging its core linker technology and innovative payloads to advance a portfolio of transformative cancer therapeutics. 

Baylink’s portfolio is comprised of products that have potential to be first-in-class and best-in class therapies with clear advantages. 

​

​Baylink is building an innovative portfolio of Degrader Antibody Conjugates, Antibody Drug Conjugates delivering traditional chemotherapy, and Dual Payload ADCs.